PacBio (NASDAQ: PACB), a leading developer of high-quality, highly
accurate sequencing solutions, today announced SPRQ, an improved
sequencing chemistry for its Revio™ long-read sequencing system.
The new chemistry will reduce Revio DNA input requirements by 4x to
500ng per sample, which enables more sample types such as saliva
extracted with PacBio’s new Nanobind protocol and tumor samples to
be sequenced with HiFi sequencing technology. It will also increase
the Revio system’s output, which together with improved analysis
methods, enables customers to reduce their sequencing cost per
genome by up to 50 percent. Paired instrument software enhancements
will also improve the accuracy of methylation calling and add
detection of new types of methylation marks providing customers
with a rich, multiomic view of every sample.
“We’ve seen tremendous demand for Revio systems over the last
two years as many more researchers have discovered the superiority
of HiFi technology in population sequencing and other human and
non-human sequencing applications,” said Christian Henry, President
and Chief Executive Officer of PacBio. “Our team has achieved
significant breakthroughs which significantly improves the
performance and reduces the cost of a HiFi human genome to less
than $500 per sample. The SPRQ chemistry opens the possibility for
more samples to be sequenced using Revio systems. This chemistry is
compatible with all Revios in the field with just a very simple
software update. Its launch is a true inflection point for
PacBio–setting a new trajectory of customer adoption and scientific
discovery.”
The SPRQ chemistry will increase the efficiency of loading on
Revio SMRT Cells, reducing DNA input requirements to just 500 ng, a
four-fold reduction. The chemistry will also improve sequencing
performance, providing a 33% increase in sequencing yield per SMRT
Cell. Collectively, these enhancements will enable each Revio
instrument to sequence up to 2,500 human whole genomes per year at
a cost of just under $500 per human genome.
"Increased yields and reduced input requirements are a big win
for our user community,” said Niall Lennon, Chair and Chief
Scientific Officer of Broad Clinical Labs. “In studies where
we had many samples that we could not have generated long reads on
before, we were able to rescue 80% of these samples using the SPRQ
chemistry. Higher success rates and lower costs for long read data
generation increases access to a wider range of scientific
applications and accelerates the pace of discovery."
In addition, a SMRT Link and instrument software upgrade paired
with the release of SPRQ chemistry provides new DNA methylation
callers that greatly increase the multiomics capabilities of every
Revio run. The software brings improved accuracy for calling 5mC,
making HiFi sequencing an attractive alternative to methylation
arrays. It also adds a new capability to call 6mA, which is used as
a marker of open chromatin in the Fiber-seq assay, providing DNA,
methylation, and chromatin accessibility all from a single DNA
input and sequencing run.
"Our lab’s Fiber-seq assay adds chromatin accessibility to the
multiomic view of a genome provided by HiFi sequencing. Fiber-seq
is seeing growing use in pangenome research, rare disease research,
and in the study of somatic variation. We are excited to see an
accurate 6mA caller on the Revio system to simplify the
computational analysis of Fiber-seq chromatin stencils and support
further adoption,” said Andrew Stergachis, MD, PhD, Associate
Professor, Medical Genetics at University of Washington.
PacBio will present data on the new SPRQ chemistry at a workshop
at the American Society of Human Genetics annual meeting taking
place in Denver, Colorado, November 5-9, 2024. The workshop on
November 8, 2024 from 12:00-1:00 p.m. MST in rooms 109-111-113, “A
new era in rare disease research: integrating HiFi sequencing into
clinical practice and population genomics,” will feature speakers
including David Miller, Vice President Global Marketing at PacBio,
Michael Eberle, Ph.D., Vice President Computational Biology at
PacBio, Carol Saunders, Ph.D., FACMG, Division Director, Clinical
& Laboratory Genetics & Genomics, Children’s Mercy Kansas
City, and Mait Metspalu, Ph.D., Director, Institute of Genomics,
Estonian Biocentre. The company will also be exhibiting all week at
booth #725.
The SPRQ chemistry and SMRT Link software are available for
order starting immediately and will begin shipping in December
2024. To learn more visit https://programs.pacb.com/ashg2024.
About PacBioPacBio (NASDAQ: PACB) is a premier
life science technology company that designs, develops, and
manufactures advanced sequencing solutions to help scientists and
clinical researchers resolve genetically complex problems. Our
products and technologies stem from two highly differentiated core
technologies focused on accuracy, quality and completeness which
include our HiFi long-read sequencing and our SBB® short-read
sequencing technologies. Our products address solutions across a
broad set of research applications including human germline
sequencing, plant and animal sciences, infectious disease and
microbiology, oncology, and other emerging applications. For more
information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use
in diagnostic procedures.
Forward-Looking Statements: This press release
may contain “forward-looking statements” within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and
the U.S. Private Securities Litigation Reform Act of 1995. All
statements other than statements of historical fact are
forward-looking statements, including statements relating to the
expected release date, uses, coverage, advantages, or quality or
performance of, or benefits or expected benefits of using, PacBio
products or technologies, such as expected release date of SPRQ,
anticipated reductions in DNA input requirements and the cost of a
HiFi genome to less than $500 per sample, increases in data output,
types and accuracy of methylation calling, chromatin accessibility,
types of samples that can be used for analysis, number of sequenced
whole genomes per year, and the related insights into multiomics;
new trajectory of customer adoption and scientific discovery; and
other future events. You should not place undue reliance on
forward-looking statements because they are subject to assumptions,
risks, and uncertainties and could cause actual outcomes and
results to differ materially from currently anticipated results,
including, challenges inherent in developing a new product,
sequencing a large number of genomes, and the difficulty of
generating discoveries across various areas of research; potential
product performance and quality issues; third-party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate PacBio's patents or proprietary rights; and other risks
associated with international operations. Additional factors that
could materially affect actual results can be found in PacBio's
most recent filings with the Securities and Exchange Commission,
including PacBio's most recent reports on Forms 8-K, 10-K, and
10-Q, and include those listed under the caption "Risk Factors."
These forward-looking statements are based on current expectations
and speak only as of the date hereof; except as required by law,
PacBio disclaims any obligation to revise or update these
forward-looking statements to reflect events or circumstances in
the future, even if new information becomes available.
ContactsFor investors: Todd Friedman
IR@pacificbiosciences.com
For media: PR@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Pacific Biosciences of C... (NASDAQ:PACB)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025